Novartis (NVS) - News Mentions

Sign up to add (NVS) to your portfolio and access more historical data.

4 33.3%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 4 100%
Gilead Sciences
Gilead Sciences
GILD		 1 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Atherosclerosis Market - Global and Regional Analysis and Forecast, 2025-2035 Featuring AstraZeneca, Novartis, Merck, Daiichi Sankyo, GSK, Sanofi, Pfizer, Bayer
May 23
“I had taken the decision confront Tsipras violently in Parliament,” Said Loverdos at the Novartis protected witnesses trial
May 22
Biologics CDMO Global and Regional Market Research Report 2025-2035, Competitive Analysis of AbbVie, AGC, Binex, Boehringer Ingelheim, Catalent, Lonza, Novartis, Parexel, Toyobo, WuXi Bio, Catalent
May 22
Lazard Asset Management LLC Has $465,000 Stake in Novartis AG (NYSE:NVS)
May 22
Analysts Set Novartis AG (NYSE:NVS) Target Price at $123.38
May 22
Dry Age-Related Macular Degeneration Market Forecast 2025-2035 with Regional and Country-Level Analysis Featuring AstraZeneca, Astellas Pharma, Novartis, Apellis Pharmaceuticals, Alkeus Pharmaceuticals and More
May 20
Equities Analysts Offer Predictions for Novartis Q2 Earnings
May 16
Here's Why Novartis (NVS) is a Strong Value Stock
May 15
Osteoporosis Drugs Market Forecast Report and Company Analysis 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann-La Roche, GSK, Merck, Novartis, Pfizer, Teva, UCB
May 15
Age-Related Macular Degeneration (AMD) Market Forecast Report and Company Analysis 2025-2033 Featuring Hoffmann - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharma, Bausch, Alimera Science
May 15
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
May 15
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
May 15
Should Value Investors Buy Novartis (NVS) Stock?
May 14
Saudi Arabia Active Pharmaceutical Ingredients Market Forecasts & Opportunities Report 2024-2025 & 2030 Featuring Pfizer, Aurobindo Pharma, Novartis, BASF, Viatris, and Novo Nordisk
May 13
Saudi Arabia Pharmaceutical CDMO Market Research Report 2025 Featuring Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, Novartis
May 13
US Healthcare Industry Outlook Report 2025 Featuring Market Influencers - Pfizer, Johnson & Johnson, Roche, AbbVie, Amgen, Novartis, Merck, Gilead Sciences, Sanofi, Bristol-Myers Squib, and B. Braun
May 12

Month over Month

Est. daily news mentions.

Apr 2025 3
Mar 2025 1
Feb 2025 2
Jan 2025 2
Dec 2024 1

How often is Novartis mentioned in the news?

Novartis was mentioned an estimated 4 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Novartis performing compared to its industry peers?

Compared to its peers, Novartis ranks in the 57th percentile when it comes to News Mentions.

Has there been an increase or decrease in news mentions of Novartis in the last month?

Novartis' was mentioned in fewer articles yesterday, compared to the same day last month.

Why is it important to track news mentions for Novartis?

By monitoring mentions in the news for Novartis, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Novartis, ultimately improving their investment strategies.

Sign up and get more insights on Novartis.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
House & Congress Trading
Earnings Calendar
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Stock performance
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
Start typing below to begin.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.